Literature DB >> 16037570

Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway.

Motohiro Kamimura1, Christiane Viedt, Alexander Dalpke, Michael E Rosenfeld, Nigel Mackman, David M Cohen, Erwin Blessing, Michael Preusch, Christian M Weber, Jörg Kreuzer, Hugo A Katus, Florian Bea.   

Abstract

Atherosclerosis is considered to be an inflammatory disease. Tissue factor (TF), a prothrombotic molecule expressed by various cell types within atherosclerotic plaques, is thought to play an essential role in thrombus formation after atherosclerotic plaque rupture. Recent studies suggest that the antiinflammatory cytokine interleukin-10 (IL-10) has many antiatherosclerotic properties. Therefore, the effects of IL-10 on TF expression in response to inflammation were investigated. Mouse macrophages were stimulated with lipopolysaccharide (LPS) in the presence or absence of IL-10. Pretreatment with IL-10 resulted in a 50% decrease in TF mRNA expression and TF promoter activity. Binding of early growth response gene-1 (Egr-1) to the consensus DNA sequence, a key transcriptional activator of TF expression in response to inflammation, and the expression of Egr-1 mRNA were also inhibited by IL-10. This inhibition was independent of the induction of suppressor of cytokine signaling protein-3 by IL-10. Macrophages that had been transfected with luciferase reporter constructs containing the murine Egr-1 5'-flanking sequence exhibited reduced reporter gene activity in response to LPS stimulation with IL-10 pretreatment. Studies with deletion constructs of the Egr-1 promoter identified the proximal serum response element SRE3 as a potential regulatory site for the IL-10 mediated suppression of Egr-1 expression. Furthermore, activation of the upstream signal-transduction elements, such as mitogen-activated protein kinase kinase (MEK) 1/2, extracellular signal-regulated kinase 1/2, and Elk-1 were also inhibited by IL-10 pretreatment. Taken together, these results demonstrate a pathway for the IL-10 mediated inhibition of TF expression during inflammation and may explain the antiatherosclerotic effects of IL-10.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037570     DOI: 10.1161/01.RES.0000177893.24574.13

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  12 in total

1.  IL-10 modulates fondaparinux inhibition of monocyte-induced thrombin generation.

Authors:  Sonia Ben-Hadj-Khalifa; Nathalie Hézard; Wassim Y Almawi; Souad Lakbakbi; Catherine Macé; Pascale Cornillet-Lefebvre; Touhami Mahjoub; Philippe Nguyen
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

2.  Tissue Engineered Vascular Graft Recipient Interleukin 10 Status Is Critical for Preventing Thrombosis.

Authors:  Gabriel J M Mirhaidari; Jenny C Barker; Jacob C Zbinden; Brevan M Santantonio; Yu-Chun Chang; Cameron A Best; James W Reinhardt; Kevin M Blum; Tai Yi; Christopher K Breuer
Journal:  Adv Healthc Mater       Date:  2020-10-19       Impact factor: 9.933

Review 3.  Expression and function of anti-inflammatory interleukins: the other side of the vascular response to injury.

Authors:  Anthony A Cuneo; Michael V Autieri
Journal:  Curr Vasc Pharmacol       Date:  2009-07       Impact factor: 2.719

4.  Rapamycin enhances LPS induction of tissue factor and tumor necrosis factor-alpha expression in macrophages by reducing IL-10 expression.

Authors:  Alyson K Baker; Ruipeng Wang; Nigel Mackman; James P Luyendyk
Journal:  Mol Immunol       Date:  2009-05-17       Impact factor: 4.407

5.  Prostaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activation.

Authors:  Manabu Minami; Koichi Shimizu; Yoshihisa Okamoto; Eduardo Folco; Marco-Lopez Ilasaca; Mark W Feinberg; Masanori Aikawa; Peter Libby
Journal:  J Biol Chem       Date:  2008-02-12       Impact factor: 5.157

6.  Posttranscriptional regulation of interleukin-10 expression by hsa-miR-106a.

Authors:  Amit Sharma; Manish Kumar; Jyotirmoi Aich; Manoj Hariharan; Samir K Brahmachari; Anurag Agrawal; Balaram Ghosh
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-23       Impact factor: 11.205

Review 7.  Beyond thrombosis: the impact of tissue factor signaling in cancer.

Authors:  Dusten Unruh; Craig Horbinski
Journal:  J Hematol Oncol       Date:  2020-07-14       Impact factor: 17.388

8.  Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with Glioma.

Authors:  Pegah Mir Seyed Nazari; Christine Marosi; Florian Moik; Julia Riedl; Öykü Özer; Anna Sophie Berghoff; Matthias Preusser; Johannes A Hainfellner; Ingrid Pabinger; Gerhard J Zlabinger; Cihan Ay
Journal:  Cancers (Basel)       Date:  2019-12-14       Impact factor: 6.639

9.  Cell-Type Specific Determinants of NRAMP1 Expression in Professional Phagocytes.

Authors:  Mathieu F M Cellier
Journal:  Biology (Basel)       Date:  2013-01-25

10.  Interdependencies among Selected Pro-Inflammatory Markers of Endothelial Dysfunction, C-Peptide, Anti-Inflammatory Interleukin-10 and Glucose Metabolism Disturbance in Obese Women.

Authors:  Joanna Janowska; Jerzy Chudek; Magdalena Olszanecka-Glinianowicz; Elżbieta Semik-Grabarczyk; Barbara Zahorska-Markiewicz
Journal:  Int J Med Sci       Date:  2016-06-25       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.